Premium
Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254
Author(s) -
Vipond Caroline,
Suker Janet,
Jones Christopher,
Tang Christoph,
Feavers Ian M.,
Wheeler Jun X.
Publication year - 2006
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.200500821
Subject(s) - strain (injury) , bacterial outer membrane , meningococcal vaccine , neisseria meningitidis , microbiology and biotechnology , vesicle , group (periodic table) , group b , group a , chemistry , biology , membrane , medicine , biochemistry , bacteria , genetics , organic chemistry , gene , escherichia coli , anatomy
Abstract In the absence of a suitable carbohydrate‐based vaccine, outer membrane vesicle (OMV) vaccines have been used to disrupt outbreaks of serogroup B meningococcal disease for more than 20 years. Proteomic technology provides physical methods with the potential to assess the composition and consistency of these complex vaccines. 2‐DE, combined with MS, were used to generate a proteome map of an OMV vaccine, developed to disrupt a long‐running outbreak of group B disease in New Zealand. Seventy four spots from the protein map were identified including the outer membrane protein (OMP) antigens: PorA, PorB, RmpM and OpcA. Protein identification indicates that, in addition to OMPs, OMV vaccines contain periplasmic, membrane‐associated and cytoplasmic proteins. 2‐D‐DIGE technology highlighted differences between preclinical development batches of vaccines from two different manufacturers.